MetaCap

Whitehawk Therapeutics Inc. (WHWK)

NASDAQ: WHWKHealth CareBiotechnology: Pharmaceutical PreparationsUSD

3.07-0.05 (-1.60%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

WHWK stock chart

Technical analysis

Key statistics

All statistics
Market cap
$181.16M
EPS (TTM)
-$1.10
52-week range
2.10 – 5.50
Day range
2.96 – 3.14
Volume / Avg
451.08K / 348.68K
Beta
—

52-week range

$2.10$5.50

WHWK stock today

On Nov 20, WHWK ended the session at $3.07, shedding $0.05 (1.60%), versus the S&P 500's 3.70% decline. Shares are 44.1% below their 52-week high of $5.50, set on May 14, 2026 and 46.2% above the 52-week low of $2.10, in the middle of the past year's range. WHWK is up 26.9% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 45.5%.

Whitehawk Therapeutics has posted a net loss over the last twelve months (EPS of -$1.10), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Whitehawk Therapeutics

Company profile

Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides three next generation antibody drug conjugates (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. David J. Lennon Ph.D.
Headquarters
Morristown, NJ
Employees
37

Financial highlights

Full financials

In fiscal 2025, Whitehawk Therapeutics generated $7.1 million in revenue, down 72.5% from fiscal 2024, its first annual decline since 2019. Whitehawk Therapeutics reported a net loss of $20.6 million, compared with a loss of $63.7 million a year earlier. Gross margin was 89.4% (up from 88.4%) and operating margin -1601.1%.

Whitehawk Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$7.14M$25.98M$24.35M$15.22M$14.00M
Growth-72.50%+6.69%+60.06%+8.69%0.00%
Net income$-20.60M$-63.69M$-65.77M$-60.51M$-110.09M
EPS (diluted)$-0.33$-2.36$-2.44$-2.69$-12.41

Analyst forecast

Forecast

Consensus (9 analysts)

buy

Avg. price target

$7.71+151.14%

  • Strong buy 1
  • Buy 5
  • Hold 3
  • Sell 0
  • Strong sell 0

Target range

Low $4.00High $10.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 9, 2026
EPS actual vs est.
$-0.23 vs $-0.24
Surprise
+4.17%

Whitehawk Therapeutics peers

Health Care sector
WHWK peer companies
CompanyPrice% ChgMarket capCompare
RNACCartesian Therapeutics Inc.6.14+4.24%$187.29Mvs WHWK
SLGLSol-Gel Technologies Ltd.55.17+2.02%$180.63Mvs WHWK
ADCTADC Therapeutics SA1.28-1.54%$180.05Mvs WHWK
NATRNature's Sunshine Products Inc.10.18+0.10%$176.41Mvs WHWK
VOGXVogenx Inc11.87-7.30%$176.33Mvs WHWK
ANTXAN2 Therapeutics Inc.5.08-2.68%$192.75Mvs WHWK
ACIUAC Immune SA1.95-8.45%$193.88Mvs WHWK
SIGASIGA Technologies Inc.2.40-9.43%$172.45Mvs WHWK

Indexes, lists and sector

Whitehawk Therapeutics stock FAQ

What is Whitehawk Therapeutics's stock price today?

WHWK last traded at $3.07 as of Nov 20, 4:00 PM EST, down 1.60% on the day. Prices are delayed at least 15 minutes.

Does Whitehawk Therapeutics pay a dividend?

No. Whitehawk Therapeutics does not currently pay a regular cash dividend.

Who is Whitehawk Therapeutics's CEO?

Dr. David J. Lennon Ph.D. is the chief executive officer of Whitehawk Therapeutics Inc., which has about 37 employees.

Has WHWK ever split its stock?

Yes. The most recent WHWK stock split was a 1-for-15 split on Aug 27, 2021.

What is the WHWK 52-week high?

The 52-week high for WHWK is $5.50 and the 52-week low is $2.10. The stock is currently 44.1% below its high.

Compare WHWK